CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

Manmeet Ahluwalia; David Peereboom; Yasmeen Rauf; Justin Lathia; Tyler Alban; Cathy Schilero; Marci Ciolfi; Corey LaForest-Roys; Lakshmi Nayak; Eudocia Lee; Patrick Wen; David Reardon

doi:10.1093/NEUONC/NOAA215.146

CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

Manmeet Ahluwalia, David Peereboom, Yasmeen Rauf, Justin Lathia, Tyler Alban, Cathy Schilero, Marci Ciolfi, Corey LaForest-Roys, Lakshmi Nayak, Eudocia Lee, Patrick Wen, David Reardon

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1093/NEUONC/NOAA215.146
State	Published - Nov 9 2020
Event	Neuro-oncology - Duration: Nov 9 2020 → …

Conference

Conference	Neuro-oncology
Period	11/9/20 → …

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1093/NEUONC/NOAA215.146License: Unspecified

Cite this

@conference{dc93d1af5e9b44bf83bbd4872778a66c,

title = "CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)",

author = "Manmeet Ahluwalia and David Peereboom and Yasmeen Rauf and Justin Lathia and Tyler Alban and Cathy Schilero and Marci Ciolfi and Corey LaForest-Roys and Lakshmi Nayak and Eudocia Lee and Patrick Wen and David Reardon",

note = "You do not currently have access to this article. Subscription prices and ordering Don't already have an Oxford Academic account? Register CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM) - 24 Hours access; Neuro-oncology ; Conference date: 09-11-2020",

year = "2020",

month = nov,

day = "9",

doi = "10.1093/NEUONC/NOAA215.146",

language = "American English",

}

TY - CONF

T1 - CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

AU - Ahluwalia, Manmeet

AU - Peereboom, David

AU - Rauf, Yasmeen

AU - Lathia, Justin

AU - Alban, Tyler

AU - Schilero, Cathy

AU - Ciolfi, Marci

AU - LaForest-Roys, Corey

AU - Nayak, Lakshmi

AU - Lee, Eudocia

AU - Wen, Patrick

AU - Reardon, David

N1 - You do not currently have access to this article. Subscription prices and ordering Don't already have an Oxford Academic account? Register CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM) - 24 Hours access

PY - 2020/11/9

Y1 - 2020/11/9

UR - https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii35/5960590

U2 - 10.1093/NEUONC/NOAA215.146

DO - 10.1093/NEUONC/NOAA215.146

M3 - Presentation

T2 - Neuro-oncology

Y2 - 9 November 2020

ER -

CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

Conference

Disciplines

Access to Document

Other files and links

Cite this